+

WO2018148724A1 - Enzyme polymérase de pyrococcus furiosus - Google Patents

Enzyme polymérase de pyrococcus furiosus Download PDF

Info

Publication number
WO2018148724A1
WO2018148724A1 PCT/US2018/017998 US2018017998W WO2018148724A1 WO 2018148724 A1 WO2018148724 A1 WO 2018148724A1 US 2018017998 W US2018017998 W US 2018017998W WO 2018148724 A1 WO2018148724 A1 WO 2018148724A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymerase
seq
nucleotide
nucleotides
dna
Prior art date
Application number
PCT/US2018/017998
Other languages
English (en)
Inventor
Jerzy Olejnik
Angela DELUCIA
Cheng-Yao Chen
Ryan Charles HELLER
Thomas William SCHOENFELD
Original Assignee
Qiagen Waltham Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiagen Waltham Inc. filed Critical Qiagen Waltham Inc.
Priority to US16/485,281 priority Critical patent/US20220127587A1/en
Priority to EP18706946.3A priority patent/EP3580350B1/fr
Publication of WO2018148724A1 publication Critical patent/WO2018148724A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase

Definitions

  • the present invention is in the field of molecular biology, in particular in the field of enzymes and more particular in the field of polymerases. It is also in the field of nucleic acid sequencing.
  • the invention relates to polymerase enzymes, in particular modified DNA polymerases which show improved incorporation of modified nucleotides compared to a control polymerase. Also included in the present invention are methods of using the modified polymerases for DNA sequencing, in particular next generation sequencing.
  • family A, B and C polymerases Three main super families of DNA polymerase exist, based upon their amino acid similarity to E. coli DNA polymerases I, II and III. They are called family A, B and C polymerases respectively. Whilst crystallographic analysis of Family A and B polymerases reveals a common structural core for the nucleotide binding site, sequence motifs that are well conserved within families are only weakly conserved between families, and there are significant differences in the way these polymerases discriminate between nucleotide analogues. Early experiments with DNA polymerases revealed difficulties incorporating modified nucleotides such as dideoxynucleotides (ddNTPs).
  • ddNTPs dideoxynucleotides
  • DNA polymerases have been modified to increase the rates of incorporation of nucleotide analogues.
  • the majority of these have focused on variants of Family A polymerases with the aim of increasing the incorporation of dideoxynucleotide chain terminators.
  • Tabor, S. and Richardson, C.C. ((1995) Proc. Natl. Acad. Sci (USA) 92:6339) describe the replacement of phenylalanine 667 with tyrosine in T. aquaticus DNA polymerase and the effects this has on discrimination of dideoxynucleotides by the DNA polymerase.
  • DNA polymerases In order to increase the efficiency of incorporation of modified nucleotides, DNA polymerases have been utilised or engineered such that they lack 3 ' -5 ' exonuclease activity (designated exo-).
  • exo- The exo- variant of 9°N polymerase is described by Perler et al, 1998 US 5756334 and by Southworth et al, 1996 Proc. Natl Acad. Sci USA 93:5281.
  • A486Y variant of Pfu DNA polymerase (Evans et al, 2000. Nucl. Acids. Res. 28: 1059). A series of random mutations was introduced into the polymerase gene and variants were identified that had improved incorporation of ddNTPs. The A486Y mutation improved the ratio of ddNTP/dNTP in sequencing ladders by 150 -fold compared to wild type. However, mutation of Y410 to A or F produced a variant that resulted in an inferior sequencing ladder compared to the wild type enzyme. For further information, reference is made to International Publication No. WO 01/38546.
  • A485L variant of 9°N DNA polymerase (Gardner and Jack, 2002. Nucl. Acids Res. 30:605). This study demonstrated that the mutation of Alanine to Leucine at amino acid 485 enhanced the incorporation of nucleotide analogues that lack a 3' sugar hydroxyl moiety (acyNTPs and dideoxyNTPs).
  • A485T variant of Tsp JDF-3 DNA polymerase (Arezi et al, 2002. J. Mol. Biol. 322:719). In this paper, random mutations were introduced into the JDF-3 polymerase from which variants were identified that had enhanced incorporation of ddNTPs.
  • WO 01/23411 describes the use of the A488L variant of Vent in the incorporation of dideoxynucleotides and acyclonucleotides into DNA.
  • the application also covers methods of sequencing that employ these nucleotide analogues and variants of 9°N DNA polymerase that are mutated at residue 485.
  • WO 2005/024010 Al also relates to the modification of the motif A region and to the 9°N DNA polymerase.
  • EP 1 664 287 Bl also relates to various altered family B type archeal polymerase enzymes which is capable of improved incorporation of nucleotides which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group, compared to a control family B type archeal polymerase enzyme.
  • the inventors have attempted to look for organisms other than 9°N. Also, to improve the efficiency of certain DNA sequencing methods, the inventors have analyzed whether such other DNA polymerases could be modified to produce improved rates of incorporation of such 3' substituted nucleotide analogues.
  • the invention relates to a polymerase enzyme according to SEQ ID NO. 1 or any polymerase that shares at least 70%, 80%, 90%, 95%, 98% amino acid sequence identity thereto, comprising a mutation selected from the group of: (i) at position 409 of SEQ ID NO. 1 : serine (S) and/or (L409S), (ii) at position 410 of SEQ ID NO. 1 : glycine (G) and/or (Y410G), (iii) at position 411 of SEQ ID NO. 1 : serine (S) (P411S), wherein the enzyme has little or no 3'-5' exonuclease activity.
  • the enzyme is from Pyrococcus furiosus.
  • polymerases also carry modifications/substitutions at position equivalent to 486 of SEQ ID NO. 1. Particularly preferred substitution is A->L. Substitutions at this position exhibit synergy with substitutions at positions 409/410/411.
  • the invention also relates to the use of a modified polymerase in DNA sequencing and a kit comprising such an enzyme.
  • incorporation means joining of the modified nucleotide to the free 3' hydroxyl group of a second nucleotide via formation of a phosphodiester linkage with the 5' phosphate group of the modified nucleotide.
  • the second nucleotide to which the modified nucleotide is joined will typically occur at the 3' end of a polynucleotide chain.
  • modified nucleotides and “nucleotide analogues” when used in the context of this invention refer to nucleotides which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group.
  • these nucleotides may carry additional modifications, such as detectable labels attached to the base moiety. These terms may be used interchangeably.
  • the term "large 3' substituent(s)” refers to a substituent group at the 3' sugar hydroxyl which is larger in size than the naturally occurring 3' hydroxyl group.
  • "improved” incorporation is defined to include an increase in the efficiency and/or observed rate of incorporation of at least one modified nucleotide, compared to a control polymerase enzyme.
  • the invention is not limited just to improvements in absolute rate of incorporation of the modified nucleotides.
  • the polymerases also incorporate other modifications and so called dark nucleotides nucleotides (non-labeled, terminating or reversibly terminating), hence, "improved incorporation” is to be interpreted accordingly as also encompassing improvements in any of these other properties, with or without an increase in the rate of incorporation.
  • tolerance for modifications on the bases could be the result of the improved properties as could be ability to incorporate modified nucleotides at a range of concentrations and temperatures.
  • the “improvement” need not be constant over all cycles.
  • “improvement” may be the ability to incorporate the modified nucleotides at low temperatures and/or over a wider temperature range than the control enzyme.
  • “improvement” may be the ability to incorporate the modified nucleotides when using a lower concentration of the modified nucleotides as substrate or lower concentration of polymerase.
  • the altered polymerase should exhibit detectable incorporation of the modified nucleotide when working at a substrate concentration in the nanomolar range.
  • altered polymerase enzyme means that the polymerase has at least one amino acid change compared to the control polymerase enzyme. In general, this change will comprise the substitution of at least one amino acid for another. In certain instances, these changes will be conservative changes, to maintain the overall charge distribution of the protein. However, the invention is not limited to only conservative substitutions. Non-conservative substitutions are also envisaged in the present invention.
  • the modification in the polymerase sequence may be a deletion or addition of one or more amino acids from or to the protein, provided that the polymerase has improved activity with respect to the incorporation of nucleotides modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group as compared to a control polymerase enzyme, such as P. furiosus wildtype (SEQ ID NO. 1), however lacking the 3 '-5' exonuclease activity.
  • a control polymerase enzyme such as P. furiosus wildtype (SEQ ID NO. 1), however lacking the 3 '-5' exonuclease activity.
  • the control polymerase may comprise any one of the listed substitution mutations functionally equivalent to the amino acid sequence of the given base polymerase (or an exo- variant thereof).
  • the control polymerase may be a mutant version of the listed base polymerase having one of the stated mutations or combinations of mutations, and preferably having amino acid sequence identical to that of the base polymerase (or an exo- variant thereof) other than at the mutations recited above.
  • the control polymerase may be a homologous mutant version of a polymerase other than the stated base polymerase, which includes a functionally equivalent or homologous mutation (or combination of mutations) to those recited in relation to the amino acid sequence of the base polymerase.
  • control polymerase could be a mutant version of the Pfu polymerase having one of the mutations or combinations of mutations listed as optional or preferable above and below relative to the Pfu amino acid sequence, or it could be a mutant version of another polymerase. It would however not comprise the S-G-S mutation claimed herein.
  • the invention also encompasses enzymes claimed herein, wherein the amino acid sequence has been altered in non-conserved regions or positions.
  • enzymes claimed herein wherein the amino acid sequence has been altered in non-conserved regions or positions.
  • One skilled in the art will understand that many amino acid positions may be altered without changing the enzyme activity.
  • nucleotide comprises a purine or pyrimidine base linked glycosidically to a sugar (ribose or deoxyribose), and one or more phosphate groups attached to the 5 ' position of the sugar.
  • Nucleosides comprise a purine or pyrimidine base linked glycosidically to a sugar (ribose or deoxyribose), but lack a phosphate group at the 5' position of the sugar. With respect to the method claims described herein, it is generally understood that a nucleoside (lacking a 5' phosphate group) cannot be incorporated by a polymerase.
  • Synthetic and naturally occurring nucleotides prior to their modification at the 3' sugar hydroxyl, are included within the definition. Labeling of the bases can occur via naturally occurring groups (such as exocyclic amines for adenosine or guanosine) or via modifications, such as 5- and 7- deaza analogs.
  • One preferred embodiment is attachment via 5- (pyrimidines) and 7- deaza (purines) propynyl group, more preferably propargylamine or propargylhydroxy group.
  • Another preferred attachment is via hydroxymethyl groups as disclosed in US9322050.
  • mutations within the amino acid sequence of a polymerase are written in the following form: (i) single letter amino acid as found in wild type polymerase, (ii) position of the change in the amino acid sequence of the polymerase and (iii) single letter amino acid as found in the altered polymerase. So, mutation of a Tyrosine residue in the wild type polymerase to a Valine residue in the altered polymerase at position 410 of the amino acid sequence would be written as Y410V. This is standard procedure in molecular biology.
  • the invention relates to a polymerase enzyme according to SEQ ID NO. 1 or any polymerase that shares at least 70%, 80%, 85%, 90%, 95% or, 98% amino acid sequence identity thereto, comprising a mutation selected from the group of: (i) at position 409 of SEQ ID NO. 1 : serine (S) and/or (L409S), (ii) at position 410 of SEQ ID NO. 1 : glycine (G) and/or (Y410G), (iii) at position 411 of SEQ ID NO. 1 : serine (S) (P411S), wherein the enzyme has little or no 3'-5' exonuclease activity.
  • the enzyme claimed shares 75%, 80%, 85%, 90%, 95%, 98%, 99%, 99,5% or 100% sequence identity with the enzyme according to SEQ ID NO. 1. These percentages do not include the additionally claimed mutations.
  • the invention also relates to a nucleic acid encoding an enzyme according to SEQ ID NO. 2, in particular with a DNA sequence according to SEQ ID NO. 3.
  • the altered polymerase will generally and preferably be an "isolated” or “purified” polypeptide.
  • isolated polypeptide a polypeptide that is essentially free from contaminating cellular components is meant, such as carbohydrates, lipids, nucleic acids or other proteinaceous impurities which may be associated with the polypeptide in nature.
  • One may use a His-tag for purification, but other means may also be used.
  • at least the altered polymerase may be a "recombinant" polypeptide.
  • the altered polymerase according to the invention may be a family B type DNA polymerase, or a mutant or variant thereof.
  • Family B DNA polymerases include numerous archaeal DNA polymerase, human DNA polymerase a and T4, RB69 and ⁇ 29 phage DNA polymerases.
  • Family A polymerases include polymerases such as Taq, and T7 DNA polymerase.
  • the polymerase is selected from any family B archaeal DNA polymerase, human DNA polymerase a or T4, RB69 and ⁇ 29 phage DNA polymerases.
  • the polymerase is from an organism belonging to the family of Thermococcaceae, preferably from the genera of Pyrococcus.
  • Such organisms include, Pyrococcus abyssi, Pyrococcus woesei, Pyrococcus yayanosii, Pyrococcus horikoshii, Pryococcus furiosus or, e.g. Pryococcus glycovorans.
  • Pyrococcus furiosus The most preferred is Pyrococcus furiosus.
  • the polymerase comprises all of the following mutations, L408S, Y409G and P410S and optionally additionally, comprises one or more of the following additional mutations (numbering for 9°N) or equivalent mutations in other polymerase families: D141A, E143A, A485L. Mutations at 141/143 positions are known to eliminate most of the exonuclease proofreading ability. Mutations at position 485 (9°N) are known to enhance incorporation of non-native nucleotides (terminator mutations); see Gardner and Jack, 2002. Nucl. Acids Res. 30:605.
  • the enzyme additionally comprises a mutation A486L in SEQ ID NO. 1.
  • Preferred is a polymerase, wherein the enzyme shares 95%, preferably even 98% sequence identity (not counting the mutations) with SEQ ID NO. 1 and additionally has the following set of mutations, (i) L409S, Y410G, P41 IS and (ii) A486L.
  • the enzyme as an amino acid sequence exactly according to SEQ ID NO. 2.
  • the modified polymerase comprises a mutation corresponding to A485L in 9°N polymerase.
  • This mutation corresponds to A488L in Vent and A486L in Pfu.
  • A486Y variant of Pfu DNA polymerase (Evans et al., 2000. Nucl. Acids. Res. 28: 1059). A series of random mutations was introduced into the polymerase gene and variants were identified that had improved incorporation of ddNTPs. The A486Y mutation improved the ratio of ddNTP/dNTP in sequencing ladders by 150-fold compared to wild type.
  • mutation of Y410 to A or F produced a variant that resulted in an inferior sequencing ladder compared to the wild type enzyme; see also WO 01/38546.
  • A485L variant of 9°N DNA polymerase (Gardner and Jack, 2002. Nucl. Acids Res. 30:605). This study demonstrated that the mutation of Alanine to Leucine at amino acid 485 enhanced the incorporation of nucleotide analogues that lack a 3' sugar hydroxyl moiety (acyNTPs and dideoxyNTPs).
  • A485T variant of Tsp JDF-3 DNA polymerase (Arezi et al, 2002. J. Mol. Biol. 322:719).
  • WO 01/23411 describes the use of the A488L variant of Vent in the incorporation of dideoxynucleotides and acyclonucleotides into DNA.
  • the application also covers methods of sequencing that employ these nucleotide analogues and variants of 9°N DNA polymerase that are mutated at residue 485.
  • the invention relates to a polymerase with the mutations shown herein which exhibits an increased rate of incorporation of nucleotides which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group and ddNTP, compared to the control polymerase being a normal unmodified enzyme.
  • nucleotides are disclosed in WO 2004/018497 A2.
  • a modified nucleotide molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3'-OH blocking group covalently attached thereto, such that the 3' carbon atom has attached a group of the structure: -O-Z is disclosed, wherein Z is any of -C(R') 2 - N(R") 2 'C(R) 2 -N(H)R", and -C(R) 2 -N 3 , wherein each R" is or is part of a removable protecting group; each R is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a
  • the claimed polymerase may be used in extension reactions and sequencing reactions very well when a novel nucleotide is used.
  • the invention relates to a method of sequencing a nucleic acid wherein the claimed polymerase is used together with the following nucleotide.
  • nucleotide has the following characteristics.
  • the nucleotide comprises a nucleobase, a sugar, and at least one phosphate group at the 5' position, wherein said nucleobase comprising a detectable label attached via a cleavable oxymethylenedisulfide linker, said sugar comprising a 3'-0 capped by a cleavable protecting group comprising methylenedisulfide.3'-0
  • the nucleobase is a non-natural nucleobase and is selected from the group comprising 7-deaza guanine, 7-deaza adenine, 2-amino,7-deaza adenine, and 2-amino adenine.
  • the cleavable protecting group is of the formula -CH 2 -SS-R, wherein R is selected from the group comprising alkyl and substituted alkyl groups.
  • the nucleotide has this structure: o B ° ' S
  • B is a nucleobase
  • R is selected from the group comprising alkyl and substituted alkyl groups
  • LI and L2 are connecting groups.
  • the invention relates to a kit comprising a DNA polymerase as disclosed herein and claimed herein, and at least one nucleotide (e.g. a deoxynucleotide triphosphate) comprising a nucleobase, a sugar, and at least one phosphate group at the 5' position, wherein said sugar comprising a cleavable protecting group on the 3'-0, wherein said cleavable protecting group comprises methylenedisulfide, and wherein said nucleotide further comprises a detectable label attached via a cleavable oxymethylenedisulfide linker to the nucleobase of said nucleotide.
  • nucleotide e.g. a deoxynucleotide triphosphate
  • Claimed is also a reaction mixture comprising a nucleic acid template with a primer hybridized to said template, a DNA polymerase according to the invention and at least one nucleotide comprising a nucleobase, a sugar, and at least one phosphate group at the 5' position, wherein said sugar comprising a cleavable protecting group on the 3'-0, wherein said cleavable protecting group comprises methylenedisulfide, wherein said nucleotide further comprises a detectable label attached via a cleavable oxymethylenedisulfide linker to the nucleobase of said nucleotide.
  • Claimed is a method of performing a DNA synthesis reaction comprising the steps of a) providing a nucleic acid template with a primer hybridized to said template, the DNA polymerase according to the invention, at least one nucleotide comprising a nucleobase a sugar, and at least one phosphate group at the 5' position, wherein said sugar comprising a cleavable protecting group on the 3'-0, wherein said cleavable protecting group comprises methylenedisulfide, wherein said nucleotide further comprises a detectable label attached via a cleavable oxymethylenedisulfide linker to the nucleobase of said nucleotide, and b) subjecting said reaction mixture to conditions which enable a DNA polymerase catalyzed primer extension reaction.
  • the invention also relates to a method for analyzing a DNA sequence comprising the steps of a) providing a nucleic acid template with a primer hybridized to said template forming a primer/template hybridization complex, b) adding DNA polymerase according to the invention, and a first nucleotide comprising a nucleobase, a sugar, and at least one phosphate group at the 5' position, wherein said sugar comprising a cleavable protecting group on the 3'-0, wherein said cleavable protecting group comprises methylenedisulfide, wherein said nucleotide further comprises a first detectable label attached via a cleavable oxymethylenedisulfide linker to the nucleobase of said nucleotide, c) subjecting said reaction mixture to conditions which enable a DNA polymerase catalyzed primer extension reaction so as to create a modified primer/template hybridization complex, and d) detecting a said first detectable label of said nucleotide in
  • step e) is performed by exposing said modified primer/template hybridization complex to a reducing agent. This can be TCEP.
  • the labelled nucleotide that is used is as follows.
  • D is selected from the group consisting of an azide, disulfide alkyl and disulfide substituted alkyl groups
  • B is a nucleobase
  • A is an attachment group
  • C is a cleavable site core
  • Li and L 2 are connecting groups
  • Label is a label.
  • the nucleobase is selected from the group of 7-deaza guanine, 7-deaza adenine, 2-amino,7-deaza adenine, and 2-amino adenine.
  • Li is selected from the group consisting of -CONH(CH 2 ) x - -CO-0(CH 2 ) x - -CONH- (OCH 2 CH 2 0) x -CO-O(CH 2 CH 2 0) x - and -CO(CH 2 ) x - wherein x is 0-10.
  • L 2 can be,
  • L 2 can be, -NH-, -(CH 2 ) X -NH-, -C(Me) 2 (CH 2 ) x NH-, -CH(Me)(CH 2 ) x NH-, -C(Me) 2 (CH 2 ) x CO, -CH(Me)(CH 2 ) x CO-, -(CH 2 ) x OCONH(CH 2 ) y O(CH 2 ) z NH-,
  • labelled nucleotide has the following structure:
  • the labelled nucleotide has the following structure:
  • the labelled nucleotide has the following structure:
  • the labelled nucleotide has the following structure:
  • the labelled nucleotide has the following structure:
  • the invention also relates to a nucleic acid molecule encoding a polymerase according to the invention, as well as an expression vector comprising said nucleic acid molecule.
  • the invention also relates to a method for incorporating nucleotides which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group into DNA comprising the following substances (i) a polymerase according to the invention, (ii) template DNA, (iii) one or more nucleotides, which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group.
  • the invention also relates to a method for incorporating nucleotides which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group into DNA comprising the following substances (i) a polymerase according to the invention, (ii) template DNA, (iii) one or more nucleotides, which have been modified at the 3' sugar hydroxyl such that the substituent is larger in size than the naturally occurring 3' hydroxyl group, wherein the blocking group comprises a disulfide preferably, methylenedisulfide.
  • the invention also relates to the use of a polymerase according to the invention in methods such as nucleic acid labeling, or sequencing.
  • the polymerases of the present invention are useful in a variety of techniques requiring incorporation of a nucleotide into a polynucleotide, which include sequencing reactions, polynucleotide synthesis, nucleic acid amplification, nucleic acid hybridization assays, single nucleotide polymorphism studies, and other such techniques. All such uses and methods utilizing the modified polymerases of the invention are included within the scope of the present invention.
  • nucleotides bearing a 3' block allows successive nucleotides to be incorporated into a polynucleotide chain in a controlled manner. After each nucleotide addition the presence of the 3' block prevents incorporation of a further nucleotide into the chain. Once the nature of the incorporated nucleotide has been determined, the block may be removed, leaving a free 3' hydroxyl group for addition of the next nucleotide. Sequencing by synthesis of DNA ideally requires the controlled (i.e. one at a time) incorporation of the correct complementary nucleotide opposite the oligonucleotide being sequenced.
  • blocking group of the sequencing nucleotides is required to ensure a single nucleotide incorporation but which then prevents any further nucleotide incorporation into the polynucleotide chain.
  • the blocking group must then be removable, under reaction conditions which do not interfere with the integrity of the DNA being sequenced. The sequencing cycle can then continue with the incorporation of the next blocked, labelled nucleotide.
  • a nucleotide and more usually nucleotide triphosphates, generally require a 3 OH-blocking group so as to prevent the polymerase used to incorporate it into a polynucleotide chain from continuing to replicate once the base on the nucleotide is added.
  • the DNA template for a sequencing reaction will typically comprise a double-stranded region having a free 3' hydroxyl group which serves as a primer or initiation point for the addition of further nucleotides in the sequencing reaction.
  • the region of the DNA template to be sequenced will overhang this free 3' hydroxyl group on the complementary strand.
  • the primer bearing the free 3' hydroxyl group may be added as a separate component (e.g. a short oligonucleotide) which hybridizes to a region of the template to be sequenced.
  • the primer and the template strand to be sequenced may each form part of a partially self-complementary nucleic acid strand capable of forming an intramolecular duplex, such as for example a hairpin loop structure.
  • Nucleotides are added successively to the free 3' hydroxyl group, resulting in synthesis of a polynucleotide chain in the 5' to 3' direction. After each nucleotide addition the nature of the base which has been added will be determined, thus providing sequence information for the DNA template.
  • modified nucleotides can act as chain terminators. Once the modified nucleotide has been incorporated into the growing polynucleotide chain complementary to the region of the template being sequenced there is no free 3'-OH group available to direct further sequence extension and therefore the polymerase can not add further nucleotides. Once the nature of the base incorporated into the growing chain has been determined, the 3' block may be removed to allow addition of the next successive nucleotide. By ordering the products derived using these modified nucleotides it is possible to deduce the DNA sequence of the DNA template.
  • Such reactions can be done in a single experiment if each of the modified nucleotides has attached a different label, known to correspond to the particular base, to facilitate discrimination between the bases added at each incorporation step.
  • a separate reaction may be carried out containing each of the modified nucleotides separately.
  • the modified nucleotides carry a label to facilitate their detection.
  • this is a fluorescent label.
  • Each nucleotide type may carry a different fluorescent label.
  • the detectable label need not be a fluorescent label. Any label can be used which allows the detection of the incorporation of the nucleotide into the DNA sequence.
  • One method for detecting the fluorescently labelled nucleotides comprises using laser light of a wavelength specific for the labelled nucleotides, or the use of other suitable sources of illumination.
  • the fluorescence from the label on the nucleotide may be detected by a CCD camera.
  • the DNA templates are immobilised on a surface they may preferably be immobilised on a surface to form a high density array.
  • the high density array comprises a single molecule array, wherein there is a single DNA molecule at each discrete site that is detectable on the array.
  • Single-molecule arrays comprised of nucleic acid molecules that are individually resolvable by optical means and the use of such arrays in sequencing are described, for example, in WO 00/06770, the contents of which are incorporated herein by reference.
  • Single molecule arrays comprised of individually resolvable nucleic acid molecules including a hairpin loop structure are described in WO 01/57248, the contents of which are also incorporated herein by reference.
  • the polymerases of the invention are suitable for use in conjunction with single molecule arrays prepared according to the disclosures of WO 00/06770 of WO 01/57248.
  • the scope of the invention is not intended to be limited to the use of the polymerases in connection with single molecule arrays.
  • Single molecule array-based sequencing methods may work by adding fluorescently labelled modified nucleotides and an altered polymerase to the single molecule array.
  • Complementary nucleotides would base-pair to the first base of each nucleotide fragment and would be added to the primer in a reaction catalysed by the improved polymerase enzyme. Remaining free nucleotides would be removed. Then, laser light of a specific wavelength for each modified nucleotide would excite the appropriate label on the incorporated modified nucleotides, leading to the fluorescence of the label. This fluorescence could be detected by a suitable CCD camera that can scan the entire array to identify the incorporated modified nucleotides on each fragment. Thus millions of sites could potentially be detected in parallel. Fluorescence could then be removed. The identity of the incorporated modified nucleotide would reveal the identity of the base in the sample sequence to which it is paired.
  • the cycle of incorporation, detection and identification would then be repeated approximately 25 times to determine the first 25 bases in each oligonucleotide fragment attached to the array, which is detectable.
  • the first 25 bases for the hundreds of millions of oligonucleotide fragments attached in single copy to the array could be determined.
  • the invention is not limited to sequencing 25 bases. Many more or less bases could be sequenced depending on the level of detail of sequence information required and the complexity of the array.
  • the generated sequences could be aligned and compared to specific reference sequences. This would allow determination of any number of known and unknown genetic variations such as single nucleotide polymorphisms (SNPs) for example.
  • SNPs single nucleotide polymorphisms
  • the utility of the altered polymerases of the invention is not limited to sequencing applications using single-molecule arrays.
  • the polymerases may be used in conjunction with any type of array-based (and particularly any high density array-based) sequencing technology requiring the use of a polymerase to incorporate nucleotides into a polynucleotide chain, and in particular any array-based sequencing technology which relies on the incorporation of modified nucleotides having large 3' substituents (larger than natural hydroxyl group), such as 3' blocking groups.
  • the polymerases of the invention may be used for nucleic acid sequencing on essentially any type of array formed by immobilisation of nucleic acid molecules on a solid support.
  • suitable arrays may include, for example, multi-polynucleotide or clustered arrays in which distinct regions on the array comprise multiple copies of one individual polynucleotide molecule or even multiple copies of a small-number of different polynucleotide molecules (e.g. multiple copies of two complementary nucleic acid strands).
  • the polymerases of the invention may be utilised in the nucleic acid sequencing method described in WO 98/44152, the contents of which are incorporated herein by reference.
  • This International application describes a method of parallel sequencing of multiple templates located at distinct locations on a solid support. The method relies on incorporation of labelled nucleotides into a polynucleotide chain.
  • the polymerases of the invention may be used in the method described in International Application WO 00/18957, the contents of which are incorporated herein by reference.
  • This application describes a method of solid-phase nucleic acid amplification and sequencing in which a large number of distinct nucleic acid molecules are arrayed and amplified simultaneously at high density via formation of nucleic acid colonies and the nucleic acid colonies are subsequently sequenced.
  • the altered polymerases of the invention may be utilised in the sequencing step of this method.
  • Multi-polynucleotide or clustered arrays of nucleic acid molecules may be produced using techniques generally known in the art.
  • WO 98/44151 and WO 00/18957 both describe methods of nucleic acid amplification which allow amplification products to be immobilised on a solid support in order to form arrays comprised of clusters or "colonies" of immobilised nucleic acid molecules.
  • the contents of WO 98/44151 and WO 00/18957 relating to the preparation of clustered arrays and use of such arrays as templates for nucleic acid sequencing are incorporated herein by reference.
  • the nucleic acid molecules present on the clustered arrays prepared according to these methods are suitable templates for sequencing using the polymerases of the invention.
  • the invention is not intended to use of the polymerases in sequencing reactions carried out on clustered arrays prepared according to these specific methods.
  • the polymerases of the invention may further be used in methods of fluorescent in situ sequencing, such as that described by Mitra et al. Analytical Biochemistry 320, 55-65, 2003.
  • the invention provides a kit, comprising: (a) the polymerase according to the invention, and optionally, a plurality of different individual nucleotides of the invention and/or packaging materials therefor.
  • Fig. 1 shows labeled analogs of nucleotides with 3'-0 methylenedisulfide-containing protecting group, where labels are attached to the nucleobase via cleavable oxymethylenedisulfide linker (-OCH 2 -SS-).
  • the analogs are (clockwise from the top left) for deoxyadenosine, thymidine or deoxyuridine, deoxycytidine and deoxyguanosine.
  • Fig. 2 shows an example of the labeled nucleotides where the spacer of the cleavable linker includes the propargyl ether linker.
  • the analogs are (clockwise from the top left) for deoxyadenosine, thymidine or deoxyuridine, deoxycytidine and deoxyguanosine.
  • Fig. 3 shows a synthetic route of the labeled nucleotides specific for labeled dT intermediate.
  • Fig. 4 shows a cleavable linker synthesis starting from an 1,4-butanediol.
  • Fig. 5 shows the measurement of polymerase performance using extension in solution and capillary electrophoresis.
  • the rate of single base terminating dNTP incorporation is measured.
  • the extended fluorescent primer is detected by capillary electrophoresis (CE).
  • CE capillary electrophoresis
  • the relative rate dNTP addition is determined by plots of fraction extended primer over time.
  • Fig. 6 shows kinetics of incorporation of nucleotide analogs (reversibly terminating dG) as measured by capillary electrophoresis assay.
  • the methodology used here is solution based assay using synthetic DNA template and synthetic primer labeled with fluorophore at 5 'end.
  • the template is specific to the nucleotide interrogated.
  • a mixture of pre-annealed primer/template, polymerase and nucleotide are incubated at temperature appropriate for the polymerase studied. After incubation an aliquot is loaded onto capillary electrophoresis system where size separation is performed using denaturing conditions and fluorescence detection. Peaks corresponding to non-extended primer, extended primer and residual nuclease activity (primer degradation) are observed in this trace indicating polymerase ability to incorporate nucleotide analog.
  • Fig. 7 shows generic universal building blocks structures comprising new cleavable linkers usable with the enzymes of the present invention.
  • PG Protective Group, LI, L2 - linkers (aliphatic, aromatic, mixed polarity straight chain or branched).
  • RG Reactive Group.
  • such building blocks carry an Fmoc protective group on one end of the linker and reactive NHS carbonate or carbamate on the other end. This preferred combination is particularly useful in modified nucleotides synthesis comprising new cleavable linkers.
  • a protective group should be removable under conditions compatible with nucleic acid/nucleotides chemistry and the reactive group should be selective.
  • an Fmoc group can be easily removed using base such as piperidine or ammonia, therefore exposing amine group at the terminal end of the linker for the attachment of cleavable marker.
  • a library of compounds comprising variety of markers can be constructed this way very quickly.
  • Fig. 8 shows incorporation of fluorescently labeled, reversibly terminating nucleotide Alexa488-dC- 3'-0-CH 2 SSCH 3 as measured by fluorescence plate based assay for JPoll22 and T9.
  • Duplex DNA was immobilized on the plate, a solution of polymerase and nucleotide was added and after incubation plate was washed and read with fluorescence plate reader (exc. 490 nm/em. 520 nm).
  • Figure 9 shows performance of Jpol 122 (SEQ ID NO. 2) as measured by sequencing KPIs and compared to legacy (T9).
  • the data shows significant improvement in average reads length and error rate for JPoll22 (SEQ ID NO. 2).
  • Fig. 10 shows kinetics of incorporation of 3'-0-CH2-SS-CH3 dA nucleotide at various concentrations by polymerase T9 and JPoll22 (SEQ ID NO. 2).
  • the data shows much faster incorporation of this reversibly terminating nucleotide by JPoll22 (SEQ ID NO. 2).
  • the combined organic extract was then washed with a saturated solution of NaHC03 (2X150 mL) in a partitioning funnel, and the organic layer was dried over Na 2 S0 4 .
  • the organic part was concentrated by rotary evaporation.
  • the reaction mixture was finally purified by silica gel column chromatography.
  • Final purification was carried out by CI8 Prep HPLC as described above resulting in ⁇ 25% yield of compound 5.
  • the mixture was separated into two equal fractions, and each was transferred to a 2000mL beaker and neutralized by slowly adding saturated K2CO3 solution until CO2 gas evolution was stopped (pH 8). The mixture was then extracted with EtOAc in a separating funnel. The organic part was then washed with saturated solution of NaHC0 3 (2X1L) followed by with distilled water (2X1L), then the organic part was dried over Na2SC>4.
  • N 4 -Benzoyl-5'-0-(tert-butyldimethylsilyl)-3'-O-(methylthiomethyl)-2'-deoxycytidine (7) (2.526g, 5.0 mmol) dissolved in dry CH2CI2 (35 mL) was added with molecular sieve-3A (lOg). The mixture was stirred for 30 minutes. It was then added with Et3N (5.5 mmol), and stirred for 20 minutes on an ice-salt-water bath. It was then added slowly with 1M SO2CI2 in CH2CI2 (7.5 mL, 7.5 mmol) using a syringe and stirred at the same temperature for 2 hours under N2-atmosphere.
  • N 4 -Benzoyl-3'-O-(ethyldithiomethyl)-5'-0-(tert-butyldimethylsilyl)-2'-deoxycytidine (8, 1.50g, 2.72 mmol) was dissolved in 50 mL THF. Then 1M TBAF in THF (3.3 mL) was added at ice-cold temperature under nitrogen atmosphere. The mixture was stirred for 1 hour at room temperature. Then the reaction was quenched by adding 1 mL MeOH, and solvent was removed after 10 minutes by rotary evaporation. The product was purified by silica gel flash chromatography using gradient 1 : 1 to l :9/Hex:EtOAc to result in compound 9.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une enzyme polymérase de Pyrococcus furiosus présentant une capacité améliorée à incorporer des nucléotides à terminaison réversible. L'enzyme comprend les mutations suivantes dans la région du motif A (SGS). L'invention concerne une enzyme polymérase conformément à la SEQ ID No. 1 ou une polymérase quelconque qui partage au moins 70 % d'identité de séquence d'acides aminés avec celle-ci, comprenant une mutation choisie dans le groupe constitué par (i) une mutation en position 409 de la SEQ ID No. 3 : sérine (S) (L409S) et/ou, (ii) une mutation en position 410 de la SEQ ID No. 3 : glycine (G) (Y410G) et/ou (iii) une mutation en position 411 de la SEQ ID No. 3 : sérine (S) (P411S), l'enzyme présentant peu ou pas d'activité exonucléase 3'-5'.
PCT/US2018/017998 2017-02-13 2018-02-13 Enzyme polymérase de pyrococcus furiosus WO2018148724A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/485,281 US20220127587A1 (en) 2017-02-13 2018-02-13 Polymerase enzyme from pyrococcus furiosus
EP18706946.3A EP3580350B1 (fr) 2017-02-13 2018-02-13 Enzyme polymérase de pyrococcus furiosus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762458397P 2017-02-13 2017-02-13
US62/458,397 2017-02-13
EP17160396.2 2017-03-10
EP17160396 2017-03-10

Publications (1)

Publication Number Publication Date
WO2018148724A1 true WO2018148724A1 (fr) 2018-08-16

Family

ID=58266977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/017998 WO2018148724A1 (fr) 2017-02-13 2018-02-13 Enzyme polymérase de pyrococcus furiosus

Country Status (1)

Country Link
WO (1) WO2018148724A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001816B2 (en) 2018-12-05 2021-05-11 Illumina, Inc. Polymerases, compositions, and methods of use
US11104888B2 (en) 2018-10-31 2021-08-31 Illumina, Inc. Polymerases, compositions, and methods of use
US11866741B2 (en) 2017-02-13 2024-01-09 IsoPlexis Corporation Polymerase enzyme from 9°N
US12077789B2 (en) 2021-08-14 2024-09-03 Illumina, Inc. Polymerases, compositions, and methods of use

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756334A (en) 1990-04-26 1998-05-26 New England Biolabs, Inc. Thermostable DNA polymerase from 9°N-7 and methods for producing the same
WO1998044152A1 (fr) 1997-04-01 1998-10-08 Glaxo Group Limited Methode de sequençage d'acide nucleique
WO1998044151A1 (fr) 1997-04-01 1998-10-08 Glaxo Group Limited Methode d'amplification d'acide nucleique
WO2000006770A1 (fr) 1998-07-30 2000-02-10 Solexa Ltd. Biomolecules en rangees et leur utilisation dans une procedure de sequençage
WO2000018957A1 (fr) 1998-09-30 2000-04-06 Applied Research Systems Ars Holding N.V. Procedes d'amplification et de sequençage d'acide nucleique
WO2001023411A2 (fr) 1999-09-30 2001-04-05 New England Biolabs, Inc. Incorporation de nucleotides modifies par des adn polymerases d'archaeon et methodes associees
WO2001038546A1 (fr) 1999-11-23 2001-05-31 Amersham Biosciences Corp Utilisation amelioree de didesoxynucleotide triphosphate par l'adn polymerase hyperthermophile issu de l'archaeon pyrococcus furiosus
WO2001057248A2 (fr) 2000-02-01 2001-08-09 Solexa Ltd. Groupes de polynucleotides et leur utilisation dans le sequencage
WO2004018497A2 (fr) 2002-08-23 2004-03-04 Solexa Limited Nucleotides modifies
WO2005024010A1 (fr) 2003-09-11 2005-03-17 Solexa Limited Polymerases modifies pour l'incorporation amelioree d'analogues nucleotidiques
WO2014142921A1 (fr) * 2013-03-14 2014-09-18 Illumina, Inc. Polymérases modifiées pour l'incorporation améliorée d'analogues nucléotidiques
US20150376582A1 (en) * 2014-06-27 2015-12-31 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
US9322050B2 (en) 2009-04-23 2016-04-26 Intelligent Bio-Systems, Inc. Hydroxymethyl linkers for labeling nucleotides

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756334A (en) 1990-04-26 1998-05-26 New England Biolabs, Inc. Thermostable DNA polymerase from 9°N-7 and methods for producing the same
WO1998044152A1 (fr) 1997-04-01 1998-10-08 Glaxo Group Limited Methode de sequençage d'acide nucleique
WO1998044151A1 (fr) 1997-04-01 1998-10-08 Glaxo Group Limited Methode d'amplification d'acide nucleique
WO2000006770A1 (fr) 1998-07-30 2000-02-10 Solexa Ltd. Biomolecules en rangees et leur utilisation dans une procedure de sequençage
WO2000018957A1 (fr) 1998-09-30 2000-04-06 Applied Research Systems Ars Holding N.V. Procedes d'amplification et de sequençage d'acide nucleique
WO2001023411A2 (fr) 1999-09-30 2001-04-05 New England Biolabs, Inc. Incorporation de nucleotides modifies par des adn polymerases d'archaeon et methodes associees
WO2001038546A1 (fr) 1999-11-23 2001-05-31 Amersham Biosciences Corp Utilisation amelioree de didesoxynucleotide triphosphate par l'adn polymerase hyperthermophile issu de l'archaeon pyrococcus furiosus
WO2001057248A2 (fr) 2000-02-01 2001-08-09 Solexa Ltd. Groupes de polynucleotides et leur utilisation dans le sequencage
WO2004018497A2 (fr) 2002-08-23 2004-03-04 Solexa Limited Nucleotides modifies
WO2005024010A1 (fr) 2003-09-11 2005-03-17 Solexa Limited Polymerases modifies pour l'incorporation amelioree d'analogues nucleotidiques
EP1664287A1 (fr) 2003-09-11 2006-06-07 Solexa Limited Polymerases modifies pour l'incorporation amelioree d'analogues nucleotidiques
US9322050B2 (en) 2009-04-23 2016-04-26 Intelligent Bio-Systems, Inc. Hydroxymethyl linkers for labeling nucleotides
WO2014142921A1 (fr) * 2013-03-14 2014-09-18 Illumina, Inc. Polymérases modifiées pour l'incorporation améliorée d'analogues nucléotidiques
US20150376582A1 (en) * 2014-06-27 2015-12-31 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AREZI BAHRAM ET AL: "Efficient and high fidelity incorporation of dye-terminators by a novel archaeal DNA polymerase mutant", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 322, no. 4, 27 September 2002 (2002-09-27), pages 719 - 729, XP002560782, ISSN: 0022-2836, [retrieved on 20020917], DOI: 10.1016/S0022-2836(02)00843-4 *
AREZI ET AL., J. MOL. BIOL., vol. 322, 2002, pages 719
DATABASE Geneseq [online] 25 February 2016 (2016-02-25), "Pyrococcus sp. DNA polymerase mutant K477M/L408A/Y409A/P410X, SEQ ID 19.", retrieved from EBI accession no. GSP:BCK66907 Database accession no. BCK66907 *
DATABASE Geneseq [online] 6 November 2014 (2014-11-06), "Pyrococcus furiosus exo polymerase protein, SEQ: 18.", retrieved from EBI accession no. GSP:BBN98964 Database accession no. BBN98964 *
EVANS ET AL., NUCL. ACIDS. RES., vol. 28, 2000, pages 1059
EVANS STEVEN J ET AL: "Improving dideoxynucleotide-triphosphate utilisation by the hyper-thermophilic DNA polymerase from the archaeon Pyrococcus furiosus", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, vol. 28, no. 5, 1 March 2000 (2000-03-01), pages 1059 - 1066, XP002164138, ISSN: 0305-1048, DOI: 10.1093/NAR/28.5.1059 *
GARDNER A F ET AL: "Acyclic and dideoxy terminator preferences denote divergent sugar recognition by archaeon and Taq DNA polymerases", NUCLEIC ACIDS RESEARCH, INFORMATION RETRIEVAL LTD, vol. 30, no. 2, 15 January 2002 (2002-01-15), pages 605 - 613, XP002309458, ISSN: 0305-1048 *
GARDNER A.F.; JACK W.E.: "Determinants of nucleotide sugar recognition in an archaeon DNA polymerase", NUCL. ACIDS RES., vol. 27, 1999, pages 2545, XP002328832, DOI: doi:10.1093/nar/27.12.2545
GARDNER; JACK, NUCL. ACIDS RES., vol. 30, 2002, pages 605
MITRA ET AL., ANALYTICAL BIOCHEMISTRY, vol. 320, 2003, pages 55 - 65
SOUTHWORTH ET AL., PROC. NATL ACAD. SCI USA, vol. 93, 1996, pages 5281
TABOR, S.; RICHARDSON, C.C., PROC. NATL. ACAD. SCI (USA, vol. 92, 1995, pages 6339

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866741B2 (en) 2017-02-13 2024-01-09 IsoPlexis Corporation Polymerase enzyme from 9°N
US11104888B2 (en) 2018-10-31 2021-08-31 Illumina, Inc. Polymerases, compositions, and methods of use
US11560552B2 (en) 2018-10-31 2023-01-24 Illumina, Inc. Polymerases, compositions, and methods of use
US11001816B2 (en) 2018-12-05 2021-05-11 Illumina, Inc. Polymerases, compositions, and methods of use
US11634697B2 (en) 2018-12-05 2023-04-25 Illumina, Inc. Polymerases, compositions, and methods of use
US12104182B2 (en) 2018-12-05 2024-10-01 Illumina, Inc. Polymerases, compositions, and methods of use
US12077789B2 (en) 2021-08-14 2024-09-03 Illumina, Inc. Polymerases, compositions, and methods of use

Similar Documents

Publication Publication Date Title
WO2018148723A1 (fr) Enzyme polymérase de pyrococcus abyssi
WO2018148727A1 (fr) Enzyme polymérase de 9°n
US20220112552A1 (en) Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequencing by synthesis
US11866741B2 (en) Polymerase enzyme from 9°N
EP3091026B1 (fr) Terminateurs réversibles à liaison disulfure
WO2018148726A1 (fr) Enzyme polymérase issue du phage t4
EP1198594B1 (fr) Extension par polymerase a l'extremite 3' de chimere de pna-adn
US8034923B1 (en) Reagents for reversibly terminating primer extension
EP2279194A1 (fr) Substrats non naturels pour polymérases pouvant supporter la synthèse enzymatique d acides nucléiques double brin à partir d une matrice d acide nucléique et procédés d utilisation
WO2018148724A1 (fr) Enzyme polymérase de pyrococcus furiosus
JP2021118748A (ja) ポリメラーゼ酵素
EP3580350B1 (fr) Enzyme polymérase de pyrococcus furiosus
US6063571A (en) Process for amplifying nucleic acids using DNA/PNA primers
US20240158767A1 (en) Polymerase enzyme from phage t4
EP3580352A1 (fr) Enzyme polymérase de pyrococcus abyssi
JP2003502013A (ja) モルホリノ−ヌクレオチドの製造方法、並びに核酸配列の分析およびラベリングのためのその使用
Olejnik et al. Polymerase enzyme from 9 N
JP4119976B2 (ja) ５位置換ピリミジンデオキシヌクレオチド誘導体、及びそれを用いた核酸の合成方法
EP1546399B1 (fr) Polyphosphates de nucleoside a phosphate terminal bloque
KR20240024924A (ko) 폴리머라제 돌연변이체 및 3'-oh 비차단 가역적 종결자와의 사용
Kielkowski New functionalized nucleic acids for application in chemical biology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18706946

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018706946

Country of ref document: EP

Effective date: 20190913

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载